Fundació n para el Estudio de las Hepatitis Virales, Madrid, Spain Hepatitis C virus (HCV) infection in the absence of detectable antibodies against HCV and of viral RNA in serum is called occult HCV infection. Its prevalence and clinical significance in chronic hepatitis B virus (HBV) infection is unknown. HCV RNA was tested for in the liver samples of 52 patients with chronic HBV infection and 21 (40 %) of them were positive for viral RNA (occult HCV infection). Liver fibrosis was found more frequently and the fibrosis score was significantly higher in patients with occult HCV than in negative ones, suggesting that occult HCV infection may have an impact on the clinical course of HBV infection.
INTRODUCTION
Hepatitis B virus (HBV) and hepatitis C virus (HCV) have common modes of transmission and thus, coinfection with HBV and HCV is not infrequent. Patients with HBV/HCV dual infection tend to develop a more severe liver disease (Zarski et al., 1998; Sagnelli et al., 2004) and there is a mutual interference between both viruses, although the inhibition of HBV exerted by HCV is more frequently observed (Sheen et al., 1992; Chu et al., 1998) . Apart from this overt dual infection, occult HBV infection [the presence of HBV DNA in the absence of HBV surface antigen (HBsAg)] is common in patients with chronic hepatitis C, and this occult HBV infection is associated with a more severe course of hepatitis C and may impair response to antiviral therapy (Cacciola et al., 1999; Mrani et al., 2007) . In recent years, a new form of HCV infection (occult HCV infection) has been identified in patients with abnormal values of liver enzymes of unknown aetiology (Castillo et al., 2004; Bokharaei-Salim et al., 2011) . This occult HCV infection is characterized by the detection of HCV RNA in liver in the absence of antibodies against HCV (anti-HCV) and of serum HCV RNA. The aetiology of this occult HCV infection is likely explained by the sporadic exposure to low infective virus doses resulting in a latent seronegative infection. Thus, anti-HCV reactivity and circulating viral RNA remain undetectable by conventional assays, although traces of antibodies against HCV core protein and very low levels of serum HCV RNA may be detectable with enhanced sensitivity tests Quiroga et al., 2009) . Besides cryptogenic chronic hepatitis, occult HCV infection also has been identified in a small cohort of patients with HBV infection (De Marco et al., 2012) but it is unknown whether occult HCV affects the severity and the clinical course of chronic HBV infection. In the present study we have investigated the prevalence and the clinical relevance of occult HCV infection in HBsAg-positive patients.
METHODS
Patients and samples. The study comprised 52 HBsAg-positive, anti-HCV and serum HCVRNA-negative patients who underwent a liver biopsy for a diagnostic purpose. After obtaining the liver sample, it was divided into two portions. One fragment was processed for histological diagnosis (Scheuer, 1991) , and for HBV DNA and HCV RNA detection by in situ hybridization. The second portion was submerged (no later than 30 s after obtaining the liver biopsy) in RNAlater (Qiagen) and stored at 220 uC until its use for HBV DNA and HCV RNA detection by real-time PCR. The clinical and histopathological data of the 52 patients are shown in Table 1 . The study was approved by our local Ethics Committee and all patients gave their written informed consent.
Serological markers. HBsAg, antibodies against HBsAg (anti-HBs), HBV e antigen (HBeAg) and antibodies against HBeAg (anti-HBe) were detected by commercially available enzyme-linked immunoassays (bioMérieux). Anti-HCV was tested by a fourth-generation assay (Innotest HCV Ab IV; Innogenetics).
HBV DNA detection by real-time PCR. Total DNA was isolated from 200 ml serum by digestion with proteinase K (1 mg ml
21
) and 1 % SDS. After phenol extraction and ethanol precipitation, the pellet was dissolved in 10 ml distilled water. Liver biopsies were homogenized in 16 TSE buffer (10 mM Tris/HCl, pH 7.5; 10 mM NaCl, 2 mM EDTA), and digested with proteinase K and SDS. After phenol extraction and ethanol precipitation, total DNA was dissolved in distilled water and its concentration adjusted to 0.1 mg ml 21 . Detection of HBV DNA was carried out by real-time PCR in a LightCycler (Roche Diagnostics), using the LightCycler FastStart DNA master HybProbe (Roche Diagnostics) and FRET probes (Leb et al., 2004) . PCR was performed in a final volume of 20 ml with 2 ml total DNA extracted from serum or with 0.2 mg total DNA extracted from liver biopsies as described by Leb et al. (2004) . For the quantification of HBV DNA, the pGBHBV2 plasmid, which contains two tandem copies of the HBV genome, was digested and linearized. Serial dilutions of HBV DNA in negative plasma were used to construct a standard curve. The detection limit of the assay was 10 copies of HBV DNA per reaction.
Quantitative HCV RNA strand-specific detection by real-time PCR. Total RNA was isolated from 250 ml serum using Trizol LS reagent (Invitrogen) and after precipitation the pellet was dissolved in 10 ml diethylpyrocarbonate (DEPC)-treated water. The SV total RNA isolation system (Promega) was used for isolation of total RNA from liver samples. After precipitation, pellets were dissolved in DEPCtreated water and RNA concentration was determined by spectrophotometry. The detection of the genomic HCV RNA strand (using 5 ml total RNA isolated from serum or 0.5 mg total RNA from liver samples) and of the antigenomic HCV RNA strand in liver, was performed by a strand-specific real-time RT-PCR using the thermostable enzyme Tth for the synthesis of cDNA at high temperature as described by Castillo et al. (2007) . Real-time PCR was performed with FRET probes in a LightCycler (Roche Diagnostics) with 2 ml cDNA in a final volume of 20 ml, using the LightCycler FastStart DNA master HybProbe kit (Roche Diagnostics), as reported by Castillo et al. (2007) . Each test run included negative controls, in which total RNA was replaced with PCR-grade water. The lower limit of HCV RNA detection in serum for our RT-PCR assay was 10 IU ml 21 with a lower limit of quantification of 30 IU ml 21 , as determined by testing serial dilutions of a HCV RNA positive serum sample, in which HCV RNA quantification was previously carried out by Cobas TaqMan HCV test (Roche Diagnostics). Standard curves constructed with 10-fold dilutions of synthetic genomic and antigenomic HCV RNA were used for the quantification of both HCV RNA stands in liver. The sensitivity of this real-time PCR was three HCV RNA copies per reaction .
In situ hybridization. The detection by in situ hybridization of the genomic HCV RNA strand and of HBV DNA in paraffin waxembedded liver sections was performed as previously described . The percentage of infected cells was determined by visual inspection and at least 1000 cells from each liver section were counted. Liver sections from patients with non-viral liver diseases (autoimmune hepatitis, alcoholic hepatitis) that tested HBV DNA and HCV RNA negative by PCR in fresh tissue were included as negative controls. 
].
Comparison of clinical, virological and histological characteristics
No differences with respect to sex, age or possible acquisition routes for HBV infection were found among HBsAg-positive patients with or without occult HCV ( ].
Levels of liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (gamma-GTP)] were higher in patients with occult HCV infection when compared to those patients without occult HCV (Table 2 ), but the differences did not reach statistical significance. The histological liver assessment showed that the portal inflammation index was HBsAg-positive patients with occult HCV infection the lobular inflammation index (1.6.±1.5) and the presence of liver fibrosis (16/21 , 76 %) were significantly higher than among patients without occult HBV (1.1.±1.6, P50.033, and 15/31, 48 %, P50.045). In addition, the liver fibrosis score was also significantly higher in patients with HCV (1.3±0.3) than in the negative ones (0.7±0.2, P50.028).
Antiviral response
A total of 34 patients (17 of them with occult HCV infection) received antiviral treatment with entecavir or tenofovir for at least 2 years. At the time of preparing this manuscript, a complete response with normalization of liver enzymes and undetectable HBV DNA in the serum has been documented in eight (47 %) and in nine (53 %) of the treated patients with and without occult HCV, respectively, Of these 17 responders, six of them (three patients with occult HCV infection) have lost HBsAg with development of anti-HBs.
DISCUSSION
Occult HCV is characterized by the presence of HCV RNA in the liver in the absence of conventional markers of HCV infection and this infection has been identified in patients with chronic hepatitis of unknown aetiology (Castillo et al., 2004; Bokharaei-Salim et al., 2011) . In the present study, we have investigated the prevalence of occult HCV infection in HBsAg-positive patients and compared the biochemical, virological and histological characteristics of the patients with and without this occult HCV infection.
We have found HCV RNA in the liver biopsy of a high proportion (40 %) of anti-HCV-negative patients with chronic hepatitis B. This prevalence of occult HCV infection in our HBsAg-positive population is higher than the 28 % prevalence reported by De Marco et al. (2012) , but these authors studied only seven HBsAg-positive patients. Furthermore, we diagnosed occult HCV infection by testing HCV RNA in the liver samples (which is the gold standard method for this purpose), while De Marco et al. (2012) detected this occult infection by monitoring HCV RNA in peripheral blood mononuclear cells, an alternative approach when a liver biopsy is not available but which does not identify all cases of occult HCV infection. As suggested elsewhere (Castillo et al., 2011) , the screening of serial peripheral blood mononuclear cells of patients who were HCV RNA negative in the basal sample could have allowed the identification of more cases with occult HCV infection.
Although with no statistical significance, serum HBV DNA levels, as well as the intrahepatic amount of HBV DNA and Occult HCV in chronic HBV infection the percentage of HBV-infected hepatocytes were decreased among our patients with occult HCV infection in comparison with the HCV-negative ones. These findings are in agreement with clinical observations in overt HBV-HCV dual infection cases that suggest a reciprocal viral interaction but with a predominant inhibitory effect of HCV on HBV replication (Sheen et al., 1992; Chu et al., 1998) and with in vitro studies which indicate that the HCV-core protein suppresses HBV gene expression and replication (Schüttler et al., 2002; Chen et al., 2003) In the group of patients with chronic HBV and occult HCV infection, levels of liver enzymes were higher than in the group without occult HCV, suggesting a possible combined effect of both viruses in liver damage. The histological assessment of the liver biopsies showed that the lobular inflammation index, the presence of liver fibrosis, as well as the fibrosis score, were significantly higher in HBsAgpositive cases with occult HCV, indicating that dual HBVoccult HCV infection could be associated with a more severe chronic liver disease. Consistent with these data, previous studies have reported that overt HBV-HCV infection and overt HCV-occult HBV infection might have an impact on the severity of the liver disease and in the clinical outcome of the patients (Zarski et al., 1998; Sagnelli et al., 2004; Cacciola et al., 1999; Mrani et al., 2007) .
It is accepted that occult HBV infection may jeopardize the response to antiviral therapy in patients with chronic hepatitis C (Mrani et al., 2007) . Among the 52 HBsAgpositive patients included in our study, 34 of them (17 with occult HCV infection) have received antiviral treatment. Our results show that response rates were similar between chronic hepatitis B patients with occult HCV infection and those without occult HCV infection and thus, it seems that occult HCV infection does not interfere with the response to antiviral therapy against HBV. However, due to the limited number of treated patients and the different antiviral regimens used, definitive conclusions await further studies. In summary, we have found that an important proportion of patients with chronic hepatitis B may have an occult HCV infection and this clinical situation seems to be associated with a more severe histological liver disease.
